Application No.: 09/513,365
Amdt. after Allow. dated 5/20/04
Reply to Not. of Allowance of 2/23/04
Sheet 1 of 3
Replacement Sheet

1/3

FIG. 1

Application No.: 09/513,365
Amdt. after Allow. dated 5/20/04
Reply to Not. of Allowance of 2/23/04
Sheet 2 of 3
Replacement Sheet

2/3

p33ING2 protein was induced by topoisomerase II inhibitor, etoposide.
(p33ING1 was not induced.)

FIG. 2

Application No.: 09/513,365
Amdt. after Allow. dated 5/20/04
Reply to Not. of Allowance of 2/23/04
Sheet 3 of 3
Replacement Sheet

3/3

**RKO
pcDNA3.1
(control)**

Sync Wizard Model
Date acquired: 20-Jul-99
File: RKO P 4-1ug 2 days
Source: RKO P 4-1ug 2 days
Case: PATIENT ID
Analysis type: Manual analysis
Prep: Unknown
G0G1:
 43.13 % Mean: 92.50
 CV: 5.03 %
G2M:
 32.50 % Mean: 176.68
 G2/G1: 1.91
S-Phase:
 24.38 % Mean: 134.93
 Compartment 1: 24.38%
Modeled Events: 7660
RCS: 5.831

**RKO
P33ING1**

Sync Wizard Model
Date acquired: 20-Jul-99
File: RKO ING1 4-1ug 2 days
Source: RKO ING1 4-1ug 2 days
Case: PATIENT ID
Analysis type: Manual analysis
Prep: Unknown
G0G1:
 67.14 % Mean: 106.56
 CV: 5.60 %
G2M:
 21.67 % Mean: 198.20
 G2/G1: 1.86
S-Phase:
 11.18 % Mean: 152.86
 Compartment 1: 11.18%
Modeled Events: 3732
RCS: 4.762

**RKO
P33ING2**

Sync Wizard Model
Date acquired: 20-Jul-99
File: RKO ING2 4-1ug 2 days
Source: RKO ING2 4-1ug 2 days
Case: PATIENT ID
Analysis type: Manual analysis
Prep: Unknown
G0G1:
 71.18 % Mean: 105.88
 CV: 4.77 %
G2M:
 19.97 % Mean: 198.00
 G2/G1: 1.87
S-Phase:
 8.85 % Mean: 152.28
 Compartment 1: 8.85%
Modeled Events: 10047
RCS: 3.209

FIG. 3